Aurobindo Pharma Ltd. announced that the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) (ANDA 202490), which was earlier tentatively approved. The product is ready for launch. Rizatriptan Benzoate Tablets 5mg and 10mg is the generic equivalent of Merck and Co's Maxalt® Tablets 5mg and 10mg and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.

Aurobindo now has a total of 171 ANDA approvals from USFDA.